An addition to treatment options for avian influenza A H5N1?

Lancet Infect Dis. 2015 Mar;15(3):251-3. doi: 10.1016/S1473-3099(15)70019-8. Epub 2015 Feb 5.

Authors

Mariana Baz¹, Kanta Subbarao²

Affiliations

¹ Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
² Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: ksubbarao@niaid.nih.gov.

PMID: 25662593
DOI: 10.1016/S1473-3099(15)70019-8

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Viral / therapeutic use*
Humans
Immunoglobulin Fab Fragments / therapeutic use*
Influenza A Virus, H5N1 Subtype / immunology*
Influenza, Human / therapy*
Male

Substances

Antibodies, Viral
Immunoglobulin Fab Fragments